Key result
Antithrombotic therapy in AF patients with coronary stents and CAA demands individualized management.
Why the study?
Managing antithrombotic treatment in patients with atrial fibrillation, coronary stents, and cerebral amyloid angiopathy with transient ischemic attacks presents a clinical dilemma.
How should antithrombotic treatment be managed in a patient with atrial fibrillation, a coronary stent, and cerebral amyloid angiopathy?
How should antithrombotic treatment be managed in a patient with atrial fibrillation, a coronary stent, and cerebral amyloid angiopathy?
This case report highlights the clinical dilemma and discusses plausible antithrombotic treatment options for a patient with concurrent atrial fibrillation, a coronary stent, and cerebral amyloid angiopathy.
Answers are grounded in this paper and cite their sources.
Case underscores individualized antithrombotic decisions in this high-risk overlap; leaves optimal regimen open pending prospective data.
We present the antithrombotic dilemma in a case with atrial fibrillation and a coronary stent and suspected transient ischemic attacks after diagnosed as a probable cerebral amyloid angiopathy and discuss plausible treatment options for the patient based on the available evidence.
No takes yet. Share an insight, caveat, or question.
RAVN et al. (2022) studied this question. Antithrombotic management in patients with atrial fibrillation, coronary stents, and cerebral amyloid angiopathy presents a complex clinical dilemma requiring individualized care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: